Uniphar Group has announced a new full-service offering to support pharmaceutical and biotech companies when launching new medicines.
The announcement coincides with the launch of Uniphar’s seventh cell and gene therapy programme on behalf of a leading pharmaceutical company.
Uniphar’s new commercialisation platform combines the group’s established expertise and tailored strategies to help clients overcome barriers to launching medicines in complex markets.
“The challenges facing pharma and biotech companies can be far-ranging when it comes to launching innovative therapies, and as a result, there’s a significant cohort of medicines that aren’t being launched in large parts of the world, despite there being a patient need,” said Brian O’Shaughnessy, chief commercialisation officer at Uniphar.
“Diverse regulatory requirements, R&D costs, pricing pressure and a lack of infrastructure are just some of the potential barriers companies can face when launching complex medicines in complex markets. It requires experience, expertise and a highly specialised supply chain.
“Being agile to work with these challenges …